Orca Bio’s T-cell therapy shows promise in haematological malignancies
The company is preparing to submit the results to the FDA this year Orca Bio has shared promising results from a late-stage study of its investigational allogeneic T-cell immunotherapy in patients with haematological malignancies. The phase 3 Precision-T trial has…
Taylor Boyd – PharmaTimes
Abzena has appointed Taylor Boyd as Chief Business Officer Abzena has announced the appointment of Taylor Boyd to the newly created role of Chief Business Officer. Boyd joins the company from Longboard Pharmaceuticals, where he most recently served as Head…
UKHSA announces new effort to tackle hepatitis C
The agency has launched a whole genome sequencing service to monitor the virus The UK Health Security Agency (UKHSA) has announced the launch of a whole genome sequencing service to tackle hepatitis C virus (HCV). The service is aimed at…
Track record – PharmaTimes
Top 5 platforms for measurement-based care in 2025 Measurement-based care (MBC) enhances clinical and therapeutic outcomes through client-reported data and evidence collection. MBC systems empower clients to report and interact with their data, giving them ownership over their healing process….
Anocca announces authorisation pancreatic cancer trial
VIDAR-1 trial marks company’s clinical-stage debut Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition to a clinical-stage organisation. The trial will evaluate advanced pancreatic cancer treatments and begins in Q2,…
Pfizer’s Talzenna therapy accepted for use within NHS Scotland
Scottish Medicines Consortium approves new option for mCRPC patients Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in…
Grifols clinical trial shows positive results for post-polio patients
Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) to treat post-polio syndrome (PPS). The study showed significant improvement in mobility…
Rxulti approved in the European Union for adolescent schizophrenia
EC extends brexpiprazole indication to include adolescents Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. The approval follows a positive opinion…
Orphelia Pharma explores other pathways for paediatric cancer treatment
Company seeks new direction after negative CHMP opinion on KIZFIZO Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)…
Minoryx doses first patient with leriglitazone in Rett syndrome study
Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of leriglitazone in treating Rett syndrome. The trial involves 24 female…
New weight-loss pill shows promising results
Oxford Medical Products targets overweight individuals Oxford Medical Products has announced positive three-month clinical trial results for Sirona, a weight-loss treatment aimed at overweight individuals and those transitioning off GLP-1 medications. The trial, conducted across three NHS hospitals, showed participants…
Dementia drug neflamapimod shows positive phase 2b trial results
CervoMed’s therapy demonstrates significant improvement in patients CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB). A new batch of neflamapimod capsules led to increased plasma drug concentrations and…
Agomab announces positive phase 2a interim results for AGMB-129
FSCD therapy meets all endpoints in interim analysis Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the ongoing STENOVA phase 2a clinical trial for AGMB-129. AGMB-129 is an oral gastro-intestinal (GI)-restricted small molecule…
Rotherham NHS Foundation Trust enhances patient engagement
Innovative digital transformation leads to significant improvements To reduce waiting lists and enhance patient communication, Rotherham NHS Foundation Trust has adopted Netcall’s Liberty for Health platform. Since its introduction, the Trust has rapidly validated waiting lists, supported patients to wait…
NHS patients receive UK-donated plasma medicines for first time in 30 years
Octapharma supports NHS in building resilient supply chain Octapharma has announced that, for the first time in almost 30 years, NHS patients are receiving medicines made from UK-donated plasma. These plasma-derived medicinal products (PDMPs), including immunoglobulins and albumin, are essential…
Leqembi enters second consultation period following NICE draft guidance update
NICE convenes third committee meeting for additional appraisal consideration Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab). Lecanemab was authorised by the MHRA for…
SECuRE trial pre-chemo participants experience PSA level drops
Cohort expansion phase commences with promising results The Safety Review Committee (SRC) has confirmed the end of the Dose Escalation phase and the start of the cohort expansion phase (phase 2) of the SECuRE trial. Based on efficacy and safety…
Centauri therapeutics selects first ABX-01 clinical candidate
Lead candidate for lung infections moves to human trials Centauri Therapeutics Limited has announced the selection of its first clinical candidate for the ABX-01 programme. The compound is designed to target serious Gram-negative bacterial lung infections. This drug candidate will…
Bas Vorsteveld – PharmaTimes
Kenvue appoints Bas Vorsteveld as Managing Director for Northern Europe Kenvue has appointed Bas Vorsteveld as Area Managing Director for Northern Europe. He will oversee Kenvue’s business in the UK, Ireland, Norway, Sweden, Denmark and Finland. Bas will manage a portfolio of iconic brands including…
Blood cancer patients face treatment access disparity
New research highlights NHS approval gap compared to other cancers Research from the Blood Cancer Alliance reveals a significant disparity in access to new blood cancer treatments on the NHS. Between 2019 and 2024, only 56% of new blood cancer…
Professor Dr Uli Brödl – PharmaTimes
Grünenthal has appointed Professor Dr Uli Brödl as CSO Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. Uli has more than 15 years of industry experience. He joins Grünenthal from…
Brainomix partners with Medtronic to enhance stroke care
New collaboration aims to integrate AI solutions for treatment Brainomix, a leader in stroke AI imaging software, has announced a strategic partnership with Medtronic Neurovascular to improve stroke care across Western Europe. The collaboration seeks to integrate advanced AI solutions…
Chain reaction – PharmaTimes
Pharmaceutical manufacturers in the UK have been navigating complex supply chains for the longest time, balancing the dual pressures of meeting patient needs and maintaining regulatory compliance. However, the introduction of the European Clinical Trials Regulation (CTR) adds a new…
Datapharm collaborates with VIDAL to improve medicines information access in France
New partnership to integrate SRD search technology Datapharm, a UK-based provider of medicines information, has announced its expansion into Europe through a strategic partnership with VIDAL. This collaboration will make Datapharm’s Scientific Response Document (SRD) Search technology accessible to healthcare…
Mukhtar Ahmed – PharmaTimes
BC Platforms has appointed Mukhtar Ahmed as CEO BC Platforms has announced that it has appointed Mukhtar Ahmed as its new Chief Executive Officer (CEO). Ahmed brings over three decades of industry experience to the role. He previously served as…
Mitazalimab shows promising survival rates in cancer study
Updated data from phase 2 study reveals survival benefit Alligator Bioscience has announced updated results from its phase 2 OPTIMIZE-1 study, showing the survival benefits of mitazalimab in combination with standard chemotherapy (mFOLFIRINOX) for metastatic pancreatic cancer. The 24-month analysis…
Microbiotica unveils new data on MB097 at AACR IO meeting
Data presented in Los Angeles showcases therapy’s potential Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles. MB097 is an oral precision microbiome medicine, currently in development as a…
Dubai garden blooms with Boehringer Ingelheim’s lung disease campaign
Awareness of interstitial lung disease raised at Miracle Garden Boehringer Ingelheim, a leading biopharmaceutical company, has teamed up with the Emirates Thoracic Society (ETS) and social media influencer Ghaith Marwan to raise awareness of Interstitial Lung Disease (ILD). The campaign…
Rishi Sunak joins Prostate Cancer Research as an ambassador
Former UK PM advocates for national screening programme Rishi Sunak has joined Prostate Cancer Research as an ambassador to champion the charity’s campaign for a national screening programme for high-risk men. The announcement follows his visit to Oxford BioDynamics’ labs,…
ICR researchers develop blood test to uncover how childhood tumours adapt
It is hoped that the approach will lead to more targeted treatments for childhood cancers Researchers from the Institute of Cancer Research (ICR) have developed a simple blood test that could be used to improve our understanding of childhood cancers….
Stephan Fritschi – PharmaTimes
Carbogen Amcis has appointed Stephan Fritschi as CEO Carbogen Amcis has appointed Stephan Fritschi, who is currently serving as the company’s Chief Alliance Officer and Deputy CEO, as Chief Executive Officer (CEO). Fritschi will take on his new role at…
FDA approves Deciphera’s Romvimza for rare tumour type
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations The US Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ Romvimza (vimseltinib) to treat adults with symptomatic tenosynovial giant cell tumours (TGCTs). The drug has been specifically…
Brent Shafer – PharmaTimes
Baxter has appointed Brent Shafer as Chair and Interim CEO Baxter International has appointed Brent Shafer, who has been serving as the company’s Lead Independent Director, as Chair and Interim Chief Executive Officer (CEO). Shafer will be stepping down from…
UK study highlights importance of GP data in understanding atrial fibrillation
The common heart condition affects approximately 1.5 million people in the UK A new UK study has highlighted the critical role of GP data in understanding atrial fibrillation (AF), the most common form of abnormal heart rhythm. The research led…
Heather Knight – PharmaTimes
Baxter has appointed Heather Knight as Executive Vice President and COO Baxter International has appointed Heather Knight, who has been leading the company’s Medical Products and Therapies unit, as Executive Vice President and Chief Operating Officer (COO). Knight holds over…
NHS England launches first-ever breast cancer screening campaign
New data has shown that around a third of women do not attend screenings after being invited NHS England has launched its first-ever breast cancer awareness campaign aimed at highlighting the benefits of screening for the disease. The drive, supported…
Bath researchers awarded Wellcome grant for psychotic disorder study
New funding to investigate cognitive decline and brain ageing The University of Bath has received a £3.5 million Wellcome grant to study cognitive decline and premature brain ageing in psychotic disorders like schizophrenia. Led by Professor Esther Walton from the…
Cambridge scientists develop ‘super test’ for prostate cancer
New test aims to revolutionise prostate cancer screening Scientists in Cambridge have developed a new ‘super test’ for prostate cancer to improve screening, diagnosis and personalised treatment. The test identifies cancerous cells, signs of early and late-stage cancer, whether it…
Illuccix therapy gets approval in the UK
Imaging agent to improve prostate cancer detection Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application for its prostate cancer PET imaging agent, Illuccix. The agent is designed for…
Andembry treatment approved across Europe
Significant progress for hereditary angioedema condition Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the first once-monthly treatment targeting factor XIIa to prevent hereditary angioedema (HAE) attacks in patients aged 12 and older….
Lynparza approved in Scotland for BRCA-mutated breast cancer patients
Treatment expands options for HER2-negative metastatic breast cancer AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish Medicines Consortium (SMC) is for treating adults with HER2-negative, locally advanced or metastatic…
Bimekizumab shows long-term efficacy in hidradenitis suppurativa
UCB’s BIMZELX reveals promising two-year data at EHSF 2025 UCB has announced impressive two-year data for BIMZELX (bimekizumab) at the 2025 EHSF. The data from the BE HEARD trials highlight sustained disease control in moderate to severe hidradenitis suppurativa (HS)….
Amlenetug receives FDA Fast Track Designation
Potential treatment for multiple system atrophy shows promise Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the US Food and Drug Administration (FDA) as a potential treatment for multiple system atrophy (MSA). This decision follows promising results…
Libtayo available in Scotland for cervical cancer patients
New immunotherapy offers hope for recurrent cervical cancer Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy treatment of adults with…
Hemgenix shows efficacy among haemophilia B patients
CSL Behring’s study reveals significant long-term benefits New data from CSL Behring’s HOPE-B study demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) gene therapy provides sustained efficacy and safety in adults with hemophilia B. The study shows that 94% of patients eliminated factor…
Capgemini unveils AI breakthrough to boost bioeconomy
New methodology may boost innovation in protein engineering Capgemini has introduced a pioneering generative AI-driven methodology for protein engineering, utilising a specialised protein large language model (pLLM) to predict the most effective protein variants. With a patent pending, this groundbreaking…
FDA grants Orphan Drug Designation to Ariceum cancer therapy
Designation follows promising preclinical data and FDA clearance Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its proprietary radiopharmaceutical, 225Ac-satoreotide, for treating…
Qureight and Avalyn launch strategic partnership in pulmonary fibrosis
Partnership aims to leverage cutting-edge technology in clinical trials Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The partnership begins with the MIST study, a phase 2b clinical trial evaluating the safety…
Novartis secures MHRA authorisation for ribociclib
Breast cancer therapy offers hope for patients at risk of recurrence Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant treatment in combination with an aromatase inhibitor (AI) for patients with HR+/HER2- early…
Rippon Ubhi – PharmaTimes
Sanofi’s Rippon Ubhi appointed new Chair of European Medicines Group Sanofi has announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). She will continue her role as Country Lead for Sanofi UK & Ireland alongside…
Algiax announces results from phase 2a trial for neuropathic pain treatment
Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released positive topline data from its phase 2a clinical trial of AP-325. The trial results…
Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
Partnership aims to create recombinant nanobodies to treat immune disorders Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with biotechnology startup FcR Therapeutics to develop recombinant nanobodies for treating autoimmune diseases. These nanobodies…
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Positive opinion issued for marketing authorisation extension The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing authorisation for a subcutaneous (SC) formulation of Rybrevant for treating non-small cell lung cancer (NSCLC). The Janssen-Cilag International NV announcement…
Aplagon secures EUR 7 million for APAC phase 2a trials
Funding led by new investors FSG and EIC Fund Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to secure this…
Research resolutions – PharmaTimes
Diversity remains high on the agenda for those designing and delivering clinical trials with the aim of bringing new treatments and medicines to market. Laura Bousfield, interim National Research Delivery Director with the National Institute for Health and Care Research…
Network of trust – PharmaTimes
How the emc supports the accessibility of medicines information Distributing reliable information about medicines is challenging for the pharma industry and the healthcare professionals (HCPs) who depend on it to provide patient care. While digitalisation has improved accessibility to this…
Janine Schuurman – PharmaTimes
Commit Biologics has appointed Janine Schuurman to its board Commit Biologics has announced the appointment of Janine Schuurman to its Board of Directors. Janine is a widely recognised scientific leader with over 25 years’ experience in antibody research, discovery and development. She is the co-inventor…
Paula Sutherland – PharmaTimes
Alliance Healthcare has appointed Paula Sutherland as Sales Director Alliance Healthcare UK has announced that Paula Sutherland has been appointed to the position of Sales Director. Paula will lead sales teams in delivering products and services to community pharmacies. She will lead Alliance Healthcare’s UK…
FDA approves new Alzheimer’s treatment regimen
Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once every four weeks intravenous (IV) maintenance dosing of LEQEMBI…
Cartesian Therapeutics announces FDA agreement for new trial
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for its phase 3 AURORA trial of…
Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX
Comparison shows improved survival rates for pancreatic cancer treatment Alligator Bioscience has announced positive outcomes from indirect treatment comparison studies, showing that mitazalimab combined with mFOLFIRINOX significantly improves overall survival (OS) for metastatic pancreatic adenocarcinoma cancer (mPDAC) patients. The OPTIMIZE-1…
Vedanta Biosciences reveals Phase 2 VE303 results
Study highlights VE303’s potential in reducing recurrent CDI Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile infection (rCDI). The study showed VE303 was…
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for treating moderate-to-severe acute pain following abdominoplasty surgery. The trial achieved its primary…
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Orphan drug designation offers development incentives and potential market exclusivity Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation provides…
AstraZeneca receives positive recommendations for lung cancer treatments
NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for its lung cancer treatments, Imfinzi and Tagrisso, benefiting patients across England and Wales….
Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease
Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset In a landmark effort, the INTERCEPT project has launched Europe’s first biomarker trial aimed at preventing Crohn’s Disease before symptoms start. This initiative, funded by the Innovative Health Initiative Joint…
EC approves lazertinib in combination with amivantamab for NSCLC patients
Combination therapy shows superior survival benefit over standard treatment The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC)…
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
Preclinical data highlights potential in treating Alzheimer’s disease AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 conference. The abstract will be presented by Gunnar Nordvall, Head of Chemistry at…
Datapharm expands into US market through partnership with phactMI
Collaboration aims to enhance accessibility of medicines information Datapharm has announced its expansion into the United States through a new partnership with phactMI. The collaboration aims to improve the quality and accessibility of medicines information for healthcare professionals (HCPs) and…
UK sees 70% increase in phase I advanced therapy clinical trials in 2024
Cell and Gene Therapy Catapult reveals significant growth in UK trials The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a 7% rise from the previous year. Particularly, phase I…
Gilead and LEO Pharma partner to develop oral STAT6 program
Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as…
Actinogen boosts trial with Cambridge Cognition’s digital suite
Partnership aims to advance Alzheimer’s research with innovative tools Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase 2b/3 XanaMIA Alzheimer’s disease trial. Building on the successful integration of Cambridge Cognition’s digital tools during…
Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials
New partnership to advance precision medicine in lung cancer diagnosis Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in global clinical trials. Aspyre Lung simplifies the detection of non-small cell lung cancer (NSCLC) biomarkers by…
Oxford Drug Design achieves in vivo validation for novel cancer treatment
Promising results from mouse study lead to expanded trials Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments using its pioneering AI…
Owlstone Medical announces $27 million USD first close in Series E financing round
Funds to accelerate commercialisation and clinical trials of diagnostic tests Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round was led by Ventura Capital, with participation from Aviva…
Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease
Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) years…
Pheno Therapeutics granted trial authorisation for MS candidate
First-in-human trial of PTD802 to commence following UK MHRA approval Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802. The small molecule therapeutic is designed to promote remyelination in neurological diseases,…
Gilead and LEO Pharma partner to develop oral STAT6 program
Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as…
AI set to revolutionise pharmaceutical R&D says GlobalData
Survey finds AI to enhance productivity and cut costs in the next 12 months AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The…
Patients pleased? – PharmaTimes
Debra is late getting up for work again. In her heart of hearts, she’s not really enjoying her job as a teaching assistant in the local primary school. There’s a lot of stress, but it’s a job. She was in…
NICE recommends olaparib for BRCA-mutated breast cancer treatment
Groundbreaking approval provides new hope for patients in England and Wales The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for NHS use in England and Wales. This treatment targets adults with…
New therapy hope for prostate cancer patients
CR-discovered NXP800 shows promise in clinical trials Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), London, found that the drug NXP800, currently in trials for ovarian and bile duct…
Angelini Ventures co-leads Series A financing in Neumirna Therapeutics
Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics. The financing, also led by Invivo Partners, saw participation from Innovestor’s Life Science Fund and other…
Cambridge Cognition highlights positive Cantab results
New FDA-approved schizophrenia treatment shows promise in clinical trials Cambridge Cognition has praised Bristol Myers Squibb for the FDA approval of Cobenfy (KarXT), a new treatment for schizophrenia. Recent research published in The American Journal of Psychiatry showcases the use…
Merck unveils new cyber-physical trust platform at CES 2025
M-Trust set to improve product safety and counterfeiting solutions Merck has launched the beta version of M-Trust, a pioneering cyber-physical trust platform, at CES 2025 to tackle product safety, traceability, and counterfeiting issues. The M-Trust platform provides enhanced product quality…
Novartis gene therapy set to enhance SMA treatment
OAV101 IT expands potential for type II SMA patients Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary endpoint in a phase 3 STEER study. This success could broaden the eligible patient population…
Amgen’s lung cancer treatment gets conditional approval
IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for IMDYLLTRA (tarlatamab), a new treatment for extensive-stage small cell lung cancer (ES-SCLC)….
New prostate cancer test cuts biopsies by 50% in US
EpiSwitch PSE shows promise in reducing unnecessary procedures Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new accurate blood test for prostate cancer. The reduction is due to the test’s marked improvement over…
FDA approves Sequana Medical’s Alfapump for ascites treatment
FDA gives green light to innovative device for liver conditions Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first…
NHS Confederation welcomes social care commission announcement
Government announces independent commission on social care The government has announced the creation of an independent commission on social care. The NHS Confederation has responded positively to this news, highlighting the crucial need for support in the sector. Matthew Taylor,…
UK regulator warns against buying weight-loss medicines without prescription
MHRA urges caution over illegal medicines from beauty salons and social media The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding the public not to buy weight-loss medicines without a prescription from healthcare professionals. This New Year, people are…
EC approves Rybrevant with Lazcluze for advanced lung cancer
New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for first-line treatment of advanced non-small cell lung cancer (NSCLC)…
German cancer centre treats first patient with Elekta Evo
New CT-guided radiotherapy system offers personalised cancer treatment Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world to treat a patient using Elekta Evo, an AI-powered adaptive CT-Linac. The 62-year-old male patient is receiving curative treatment for…
MindMed begins phase 3 study of MM120 for anxiety disorder
First patient dosed in landmark trial for GAD treatment MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety Disorder…
Beckley Psytech announces positive results for ELE-101 in depression trial
Phase 2a study shows promising antidepressant effects Beckley Psytech has announced positive topline results from its phase 2a study of ELE-101, a synthetic intravenous (IV) formulation of psilocin benzoate, for patients with Major Depressive Disorder (MDD). The study demonstrated that…
CSL receives positive opinion for garadacimab in hereditary angioedema
New treatment could revolutionise care for HAE patients Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on garadacimab, recommending its marketing authorisation as…
Leriglitazone meets primary endpoint in pivotal cALD trial
Promising trial results support marketing authorisation application Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD). The companies plan to file for European Marketing…
Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor, to assess its safety and efficacy in patients with advanced KRAS G12C-mutated solid tumours….
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Promising results set stage for European marketing authorization Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for paediatric patients with cerebral adrenoleukodystrophy (cALD). The companies plan to file for European Marketing…
iOnctura achieves new clinical milestones in uveal melanoma therapy
Successful phase 1 study highlights potential of roginolisib iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing the clinical activity and long-term safety of roginolisib in patients with uveal melanoma. The data will be presented at the…
CatalYm shows potential of visugromab for treating cachexia
New findings presented at international SCWD conference CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference on Sarcopenia, Cachexia & Wasting Disorders (SCWD). The data from the ongoing phase 1/2a GDFATHER trial…
Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis
New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its T-regulatory cell therapy candidate, CK0804, at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH). The results…
Poolbeg Pharma presents positive results for POLB 001
promising pre-clinical data on preventing cytokine release syndrome Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at the 66th American Society of Hematology (ASH) Annual Meeting. The study showed that all doses of POLB 001 significantly reduced…
Imfinzi receives NICE recommendation for lung cancer treatment
Trial results lead to new treatment option for lung cancer AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with resectable non-small cell lung cancer (NSCLC). This decision is based on positive results from…
NICE endorses Neuraxpharm’s ublituximab for treating MS
New antibody therapy shows promise in managing condition Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab (BRIUMVI®) for the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval marks a significant milestone…
Teva’s Ajovy shows positive results in preventing pediatric migraines
Phase 3 trial indicates significant efficacy and safety for children and adolescents Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and safety of AJOVY (fremanezumab) in preventing episodic migraines in children and…
Everest therapy shows promise in nephropathy trial
Data highlights effectiveness of EVER001 in treating pMN Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine kinase (BTK) inhibitor, for treating primary membranous nephropathy (pMN). The data, available as of…
Antag Therapeutics secures €80 million in weight loss therapy financing
Versant Ventures leads investment round to advance drug Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings,…
Orbit Discovery and Evergreen Theragnostics expand research collaboration
Partnership aims to develop new radiopharmaceuticals for cancer treatment Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in Springfield, NJ, USA, have announced the expansion of their collaborative research agreement. This partnership seeks to discover new targeting peptides…
KIMMTRAK recommended for funding by NICE for uveal melanoma patients
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS. This marks a significant reversal of last year’s negative decision,…
Pharma giants vie for oral GLP-1R approval
Race to create first oral drug for obesity intensifies The competition to gain approval for the first oral GLP-1R drug for obesity is heating up, with four phase 3 trials currently in progress, according to GlobalData. Obesity, defined as an…
OGT launches enhanced genetic profiling panel for CLL
New SureSeq CLL + CNV V3 panel improves understanding of CLL OGT has announced the launch of its enhanced SureSeq CLL + CNV V3 Panel, which offers more comprehensive genetic profiling for chronic lymphocytic leukaemia (CLL) samples. This new panel…
UK grants promising innovative medicine status to CIDP drug
Therapy for autoimmune disorder shows potential Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating chronic inflammatory demyelinating polyneuropathy (CIDP). This designation signals…
New injection offers hope for asthma and COPD attacks
Injection significantly reduces need for further treatment A new treatment for asthma and COPD attacks could revolutionise patient care, scientists say. An injection given during attacks is more effective than the current steroid tablet treatment, reducing the need for further…
Code makers – PharmaTimes
2024 ABPI Code update has launched – what’s next for pharma and QR codes? The long-anticipated update to the ABPI Code of Practice has launched, with the real game changer landing in Clause 12.1, which reads: ‘In printed material, prescribing…
Rab Prinjha – PharmaTimes
Curve Therapeutics has appointed Rab Prinjha as Chief R&D Officer Curve Therapeutics has appointed Rab Prinjha as Chief Research and Development (R&D) Officer. Rab is a proven R&D leader with a more than 20-year track record of success leading drug discovery programmes and collaborations pioneering research…
Mind the gap
How industry and the NHS can work together to bridge the diagnostic gap in COPD
To be precise – PharmaTimes
How oncology therapies can stand out in a diverse, uncertain landscape The oncology field is rapidly evolving, particularly with the rise of precision medicines and new targeted treatments. As the field becomes more crowded, many drug developers are diversifying their…
Mikkel Wandahl Pedersen – PharmaTimes
Commit Biologics has appointed Mikkel Wandahl Pedersen as CSO Commit Biologics has announced the appointment of Mikkel Wandahl Pedersen as Chief Scientific Officer (CSO). Mikkel is a seasoned R&D executive and scientific leader with over two decades of experience in…
Dr Lara Boyd – PharmaTimes
Tessellate BIO has appointed Dr Lara Boyd as CBO Tessellate BIO has appointed Dr Lara Boyd as Chief Business Officer. Lara joins Tessellate BIO from F-star Therapeutics, an innovation-focused biotech company dedicated to delivering next-generation multispecific antibody therapeutics, where she held a…
4 ways AI is shaping the future of Life Sciences
There’s no denying it; pharma is in its innovation era. The life sciences industry is already undergoing a massive revolution, thanks to the rapid integration of artificial intelligence (AI). We’re experiencing a transformation that will likely redefine every aspect of…
Dr Daniel Mahony – PharmaTimes
Mahony will continue as the UK government’s Life Sciences Investment Envoy The Department for Science, Innovation and Technology has announced that Dr Daniel Mahony will continue as the UK government’s Life Sciences Investment Envoy. Mahony has more than 25 years…
Cytomos raises $5m to scale up cell analysis technology production
The biotech will use the funding to drive sales of its first commercial product Cytomos has announced that it has raised $5m in an oversubscribed funding round to scale up production of its cell analysis technology. The Edinburgh-based biotech said…
Anthony Harnden – PharmaTimes
The MHRA has appointed Anthony Harnden as Chair The Medicine and Healthcare products Regulatory Agency (MHRA) has appointed Anthony Harnden, Professor of Primary Care in the Nuffield Department of Primary Care Health Sciences at the University of Oxford, as its…
Ardena’s expanded nanomedicine facility granted full GMP approval
The Netherlands facility is designed to handle a wide range of nanomedicines, including lipid-based nanoparticles Ardena has announced the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in the Netherlands by the Dutch Healthcare Authority. The Oss…
Siva Anandaciva – PharmaTimes
The King’s Fund has appointed Siva Anandaciva as Director of Policy, Events and Partnerships The King’s Fund has appointed Siva Anandaciva, its current Chief Analyst, as Director of Policy, Events and Partnerships. Anandaciva, who is expected to take up the…
New PAGB research highlights importance of self-care for easy-to-treat conditions
The census found that 56% of people visit their GP for a UTI and 27% for thrush New research from PAGB has revealed that 22% of people do not think of self-care as their first option for easy-to-treat conditions. This…
Dr Rima Makarem – PharmaTimes
Somerset NHS Foundation Trust has appointed Dr Rima Makarem as Chair Somerset NHS Foundation Trust has appointed Dr Rima Makarem, who has 15 years of experience working at board level in the NHS, as its new Chair. Makarem initially trained…
Teva and Immunai partner to improve clinical decision making
The companies will focus on mechanisms of action, dose selection and biomarker analyses Teva Pharmaceuticals and artificial intelligence (AI)-driven Immunai have entered into a partnership aimed at optimising clinical trials in immunology and immuno-oncology. The multi-year collaboration will utilise Immunai’s…
AC immune announces positive trial results for early Parkinson’s treatment
Therapy shows high efficacy in initial trial phase AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of ACI-7104.056, an anti-alpha-synuclein (a-syn) active immunotherapy for early Parkinson’s disease (PD). The trial, involving over 30…
Osivax begins phase 2a booster trial for influenza vaccine
First participant vaccinated in study of ovx836 booster dose Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious viruses, has vaccinated the first participant in its phase 2a clinical trial of OVX836. This broad-spectrum influenza vaccine candidate is…
Vivolta and Neurochase to produce brain therapy catheters
New long-term partnership to address neurological disorder treatments Vivolta, a specialist in medical electrospinning solutions, has entered a long-term partnership with UK-based Neurochase to manufacture electrospun micro-catheters for advanced brain therapies. This partnership aims to enhance the treatment of neurological…
Microbiotica begins human trials for ulcerative colitis treatment
First patient dosed in phase 1b trial of MB310 therapy Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in its Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis (UC) patients. This international trial…
Scottish medicines consortium approves CAR T-cell therapy for blood cancer
First car t-cell therapy accepted for second-line treatment in Scotland The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). This…
Lupin to develop near-zero global warming inhalers
Eco-friendly inhalers aim to reduce environmental impact Lupin Healthcare UK Ltd has announced plans to reformulate its pMDI inhalers with a near-zero global warming potential propellant as part of their commitment to achieving net-zero status by 2045. This development aligns…
Infinitopes to showcase cancer vaccine breakthroughs at SITC
Insight into double-blind, phase i/ii clinical trial for oesophageal cancer Infinitopes, an integrated cancer biotech firm, will present its pioneering cancer vaccine development at the Society for Immunotherapy of Cancer (SITC) 2024 in Houston, US, from 6-10 November. The Oxford-based…
SMC recommends Yselty for treating uterine fibroids
New treatment option approved for women in Scotland The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for treating moderate to severe symptoms of uterine fibroids (UFs) in women of reproductive age. This decision means eligible women across Scotland can…
Dr Jane Rhodes – PharmaTimes
AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer (CEO) and member of the Board, and Magnus Ivarsson as Chief Translation and Early Development Officer. Jane is an accomplished leader with 25 years of experience in the…
Elsevier backs Pistoia Alliance for AI in drug discovery
New initiatives to tackle AI-related challenges in life sciences Elsevier, a leader in information and analytics, has announced its support for The Pistoia Alliance in promoting safe and responsible AI adoption in drug discovery. This effort aims to address key…
New study to assess mpox vaccine in pregnant women and infants
Trial to evaluate safety and efficacy of MVA-BN vaccine A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and infants is set to launch in the Democratic Republic of Congo (DRC). This research could expand…
MHRA grants approval for bladder cancer drug erdafitinib
New therapy targets specific genetic alterations, promises extended survival Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic urothelial carcinoma (UC) harbouring FGFR3…
Arcellx to present positive data on multiple myeloma treatments
Phase 1 and 2 studies show promising results for anito-cel therapy Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on anitocabtagene autoleucel (anito-cel) for treating relapsed or refractory multiple myeloma. These…
A rare opportunity – PharmaTimes
Importance of continuous collaboration with rare disease communities At Blueprint Medicines, we aim to make a significant difference in patients’ lives by solving critical medical problems. Since the company’s inception, we have focused on addressing the burden faced by people…
Trial transformers – PharmaTimes
Building strong partnerships with sites for more effective clinical trials When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced…
Anthony Hemmerdinger – PharmaTimes
Walgreens Boots Alliance appoints Anthony Hemmerdinger as MD, UK and Ireland Walgreens Boots Alliance has announced the appointment of Anthony Hemmerdinger as Managing Director of Boots UK and Ireland. This follows the announcement in July that Seb James would be stepping down in November, after…
UK dementia clinical trial participation set to boost by ‘tens of thousands’
The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the UK Dementia Research Institute and Health Data Research UK and funded by the Medical Research Council, will receive £20m of…
NICE recommends remote monitoring technology for heart failure patients
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020 The National Institute for Health and Care Excellence (NICE) has announced that people with heart failure can now stay healthier remotely through advanced remote monitoring technology…
WHO report highlights resurgence of tuberculosis
Approximately 8.2 million people were diagnosed with the infectious disease in 2023 The World Health Organization’s (WHO) newly published report has placed tuberculosis (TB) as the leading infectious disease killer in 2023, surpassing COVID-19. Newly identified TB cases climbed to…
Calluna Pharma completes successful phase 1 trial of new fibrotic disease drug
CAL101 shows promising results and is set to enter phase 2 development Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and fibro-inflammatory…
NICE recommendation for new Alexion PNH treatment
danicopan shown to improve haemoglobin levels and reduce anaemia Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral Factor D inhibitor can now…
Laura Vergani – PharmaTimes
Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined as Senior Vice President of Global Communications & Public Affairs. Laura brings a proven track record of successful experience from…
Darzalex subcutaneous regimen approved by European Commission
New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for patients with newly diagnosed multiple myeloma (NDMM) who are…
Ian Keith – PharmaTimes
Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith, who has been supporting the company as a Business Consultant since the beginning of 2024, as its new Finance and Business Services…
Valneva Scotland announces year-long support for local cancer charity Team Jak
The company’s workforce will volunteer and fundraise for Team Jak throughout the year Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide year-long…
Learna and University of Wolverhampton launch flexible healthcare courses
The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University of Wolverhampton have partnered to launch five new master’s and postgraduate diploma healthcare programmes. The flexible, online courses are designed to allow…
NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for Health and Care Excellence (NICE) has issued guidance recommending Santen’s Roclanda for use in patients with primary open-angle glaucoma (POAG)…
Transgene’s cancer vaccine trial shows mixed results
Phase 2 study of TG4001 shows promise in cervical cancer patients Transgene, a biotech company specializing in virus-based immunotherapies for cancer, has announced that its phase 2 trial of TG4001 in combination with avelumab did not meet its primary objective…
Vivan renews five-year lease at UK biotech hub White City Place
The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to life sciences companies including Novartis and…
New £4.5m initiative launched to address UK medicines manufacturing skills shortage
The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage in the UK’s medicines manufacturing industry. The Resilience Centre of Excellence for UK Medicines Manufacturing Skills…
Richard Hopkins – PharmaTimes
NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its new Chief Executive Officer. Hopkins has more than 14 years of experience spanning industry, government and academia. He joins the…
HBC Immunology shares promising results for prostate cancer co-therapy
There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour activity of Pfizer/Astellas’ androgen receptor inhibitor Xtandi (enzalutamide) in prostate…
Alleo and Ubiquigent unite to accelerate drug discovery
Partnership to harness AI for DUB-focused preclinical programmes
Celltrion unveils promising dose escalation results for subcutaneous infliximab
Study reveals potential new strategy for managing inflammatory bowel disease
Lundbeck to acquire Longboard Pharmaceuticals in strategic deal
Acquisition to enhance Lundbeck’s neuroscience pipeline Lundbeck has announced a significant step forward in its Focused Innovator strategy with the acquisition of Longboard Pharmaceuticals. This strategic deal, valued at approximately USD 2.6 billion, aims to enhance Lundbeck’s capabilities in treating…
Sanofi launches high-dose flu vaccine in the UK
New vaccine aims to protect older adults from severe flu complications Sanofi has announced the launch of its high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK. This vaccine is designed for people aged 65 and older, as well as…
Johnson & Johnson myeloma drug recommended for NHS use
Teclistamab offers hope for patients exhausting treatment options Teclistamab (Tecvayli), a drug manufactured by Johnson & Johnson, has received a positive recommendation from NICE for fourth-line use on the NHS in England and Wales. This new treatment is for myeloma,…
Heart patient goes home hours after live-streamed valve replacement
Sheffield cardiologists demonstrate cutting-edge TAVI procedure Cardiologists at Sheffield Teaching Hospitals NHS Foundation Trust have performed a cutting-edge heart valve replacement procedure live to an international audience. The streamlined transcatheter aortic valve implantation (TAVI) highlighted Sheffield’s leading role in cardiovascular…
Purespring Therapeutics secures £80 million in Series B funding
New investment to advance gene therapies for kidney diseases Purespring Therapeutics has raised £80m in an oversubscribed Series B financing round. Syncona Ltd, a leading life science investor, committed £19.9m as part of a syndicate led by Sofinnova, alongside Gilde…
Astellas and AviadoBio announce exclusive gene therapy deal
AviadoBio to receive up to £1.8 billion in potential payments AviadoBio and Astellas Pharma have entered into an exclusive option and licence agreement for AVB-101, an investigational gene therapy targeting frontotemporal dementia (FTD). The deal, announced today, could see AviadoBio…
Kyowa Kirin announces positive interim data for lymphoma treatment
Real-world studies show effectiveness of mogamulizumab in routine practice Kyowa Kirin International (KKI) has announced positive interim findings from three real-world studies on mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma (CTCL). The data will be presented at the European Organisation for…
Scottish patients first in UK to access new lung cancer treatment
Scottish Medicines Consortium recommends pembrolizumab The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy for adults with non-small cell lung carcinoma (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy. This…
FluoGuide submits clinical trial application for head and neck cancer treatment
Biotech company moves forward with phase 2 trial for precision cancer surgery Copenhagen-based biotech company FluoGuide A/S has announced the submission of a Clinical Trial Application (CTA) for a phase II trial in head and neck cancer, specifically oral squamous…
AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference
Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid AlzeCure Pharma AB, a company specializing in drugs for nervous system diseases, announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the Clinical Trials…
ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study
Largest real-world study demonstrates significant survival advantage In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23% at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer…
IRLAB’s new drug shows promise in treating apathy in Parkinson’s patients
Phase 1 trial of IRL757 demonstrates good absorption and safety profile IRLAB Therapeutics AB has announced the successful completion of the first part of its Phase I clinical trial for IRL757, a drug candidate aimed at treating apathy in patients…
Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy
ISM001-055 shows promise in improving lung function among patients Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, has announced positive preliminary results from its Phase 2a clinical trial of ISM001-055. This first-in-class small molecule targets TNIK (Traf2- and Nck-interacting…
European Commission approves Yuvanci for pulmonary arterial hypertension treatment
Janssen-Cilag therapy becomes the first single tablet combination therapy for PAH in europe The European Commission has approved Yuvanci (macitentan 10 mg and tadalafil 40 mg), a single tablet combination therapy (STCT) for the long-term treatment of pulmonary arterial hypertension…
Great company – PharmaTimes
ICON celebrates 2024 ‘company of the year’ win ICON continues to celebrate its achievement at the 2024 Clinical Researcher of the Year Awards, where we were honoured to receive the ‘company of the year’ title in the International PharmaTimes competition….
Lots in translation – PharmaTimes
Harnessing vital patient data for precision in clinical trials In clinical research, leveraging patient data has become a critical factor to improve the design, execution and outcome of clinical trials. Collecting data is no longer enough; the true challenge lies…
Dr Alex Dickinson – PharmaTimes
Sphere Fluidics has appointed Dr Alex Dickinson to its Board of Directors Sphere Fluidics has announced the appointment of Dr Alex Dickinson to its Board of Directors as a Non-Executive Director (NED). Alex is a seasoned executive bringing substantial experience from the intersection…
Oxford drug design secures funding to combat cystic fibrosis lung infections
£3m programme to accelerate new antimicrobial treatment Oxford Drug Design has been awarded a share of a £3 million Collaborative Discovery Programme (CDP) by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. This initiative, funded by the not-for-profit medical research…
Sheffield A&E to implement life-saving HIV and hepatitis testing
New government scheme to offer routine opt-out blood tests Starting next week, Sheffield’s Northern General Hospital A&E Department will begin routine opt-out testing for HIV, hepatitis B, and hepatitis C for patients aged 16 and over. This initiative, commencing on…
Dr Amy Walker – PharmaTimes
4basebio has announced Dr Amy Walker as Chief Operating Officer 4basebio has announced the appointment of Dr Amy Walker as Chief Operating Officer of the company. Amy joined 4basebio in November 2020 and has served as the Vice President of…
Fabio Gratton – PharmaTimes
minds + assembly has appointed Fabio Gratton as an Advisor minds + assembly welcomes Fabio Gratton as an Advisor to its Board of Directors. Fabio brings 25 years of expertise in founding and scaling healthcare digital agencies to minds +…
AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment
International trial marks leap forward in chemotherapy-induced neuropathy care In a landmark announcement from Paris, AlgoTherapeutix (AlgoTx) has heralded the successful completion of its international phase 2 trial for ATX01, a novel therapeutic aimed at treating chemotherapy-induced peripheral neuropathy (CIPN)….
Cancer Grand Challenges launches global initiative to take on toughest problems
International think tanks to shape future of cancer research funding Cancer Grand Challenges, a pioneering initiative co-founded by Cancer Research UK and the US National Cancer Institute (NCI), has launched a global search to identify the most pressing challenges in…
Sundip Chahal – PharmaTimes
Milieu Insight has appointed Sundip Chahal as Chief Executive Officer Milieu Insight has appointed Sundip Chahal (pictured left), former YouGov Global Chief Operating Officer, as Chief Executive Officer. Chahal brings extensive experience to the position, which he takes on after…
Oncologica to advance urine-based prostate cancer screening test
There is currently no national screening programme for the disease in the UK Oncologica has developed a urine-based screening test for prostate cancer and has launched a funding drive to support its advancement. The technology, ProstateFocus, uses the Cambridge-based company’s…
FlyPharma Europe, Vienna – October 2024 conference
The conference will return to Vienna AirportCity on 23 to 24 October 2024 Samedan has announced that on 23 to 24 October 2024, its FlyPharma Conference will make a welcome return to Office Park 4, Vienna AirportCity, Austria. FlyPharma invites…
NHS Trust to evaluate AI software for prostate cancer diagnosis
It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time Leeds Teaching Hospitals NHS Trust (LTHT) has announced that it is piloting a new artificial intelligence (AI) and machine learning software system for prostate…
Jane Osbourn – PharmaTimes
Alchemab has appointed Jane Osbourn as Chief Executive Officer Alchemab Therapeutics has appointed Jane Osbourn, the company’s Co-Founder and Chief Scientific Officer, as Chief Executive Officer and Member of the Board. Osbourn brings over 30 years of biopharmaceutical industry experience…
UKRI’s MRC awards £27.4m to University of Dundee research unit
The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension The UK Research and Innovation’s (UKRI) Medical Research Council (MRC) has awarded £27.4m to a University of Dundee-based cell signalling and disease research centre to…
Russell Abberley – PharmaTimes
ABPI has appointed Russell Abberley as Acting President The Association of the British Pharmaceutical Industry (ABPI) has appointed Russell Abberley as Acting President. Abberley, who is General Manager of Amgen UK and Ireland, has over 25 years of life sciences…
WHO adds first mpox vaccine to prequalification list
The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex The World Health Organization (WHO) has announced that it has added Bavarian Nordic’s mpox vaccine to its list of prequalified vaccines. The decision is expected to facilitate timely…
Nxera and Cancer Research UK to present promising cancer drug trial at ESMO
Innovative immunotherapy drug HTL0039732 shows potential in trials Nxera Pharma and Cancer Research UK are set to present their ongoing Phase 1/2a clinical trial of the cancer immunotherapy drug HTL0039732 at the European Society for Medical Oncology (ESMO) Congress 2024…
World Sepsis Day 2024 highlights need for better sepsis treatments
GlobalData emphasises importance of Improved clinical trials World Sepsis Day, observed annually on 13 September, aims to raise awareness about sepsis, a life-threatening condition that claims millions of lives each year. Sepsis results from a dysregulated immune response to infection,…
Chemical reaction – PharmaTimes
Chemistry is the cornerstone of modern civilisation, playing a crucial role in virtually every aspect of our lives. From the food we eat and the water we drink to the medicines which save lives and the clothes we wear; the…
Centessa reports positive phase 1 clinical data for ORX750
Promising results for novel orexin agonist in sleep-deprived volunteers Nxera Pharma, formerly known as Sosei Group, has announced that its partner, Centessa Pharmaceuticals, has reported encouraging interim results from a Phase 1 clinical trial of ORX750. The novel orexin receptor…
HRT linked to reduced psychosis relapse risk in menopausal women
New study highlights potential benefits of menopausal hormone therapy A recent study published in the American Journal of Psychiatry suggests that menopausal hormone therapy (HRT) may reduce the risk of psychosis relapse in menopausal women. The research, led by Bodyl…